A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors. - Wikidata - awgldk - TriplyDB

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

http://www.wikidata.org/entity/Q38801820

about

A case report of severe calciphylaxis - suggested approach for diagnosis and treatment.Calciphylaxis in peritoneal dialysis patients: a single center cohort study.Role of Vitamin D in Uremic Vascular Calcification.Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis.Calcific Uremic Arteriolopathy Revisited.Increased Bone Morphogenetic Protein Signaling in the Cutaneous Vasculature of Patients with Calciphylaxis.Clinical characteristics and risk factors associated with mortality in calcific uremic arteriolopathy.Briefly Noted.K-alcification Protection in Dialysis Patients: The Underestimated Phenomenon of Vitamin K Deficiency.Multi-intervention management of calcific uremic arteriolopathy in 24 patients Differences in Risk Factors and Prevalence of Vascular Calcification between Pre-Dialysis and Hemodialysis Balkan Nephropathy Patients Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges

P2860

Q30353115-9D261169-7464-42F7-8B08-7A98C9AB7284 Q37279635-BB8B7836-8EFD-48CC-91F3-06EF12C7ADBE Q37670797-2E99A8F0-62A8-4F42-AFC7-8DB509235652 Q40397629-AD3B89CA-F235-4644-B9B6-1D46E78AE96D Q42722933-9FAB861B-039F-4E14-9AF6-901B7028D1DB Q47231423-B4CBFC98-0330-448A-A4A0-ADAEA8462E0B Q50067332-19292236-A314-4E22-98B4-C2FE6D6235C2 Q54534876-54A072E6-4C95-4691-AE82-9EE0E016DFBF Q54836906-B3798EBA-5BCE-48AD-AB36-160B0342481B Q57053843-0CD07EA4-D56D-4FFE-AF38-81D31F4A1234 Q57826011-BB86FCC9-CCEB-4336-B341-9AB0AFEE0364 Q58749820-2820FBB0-C267-443C-9B41-44976BC0F0C3

P2860

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

http://www.wikidata.org/entity/Q38801820

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

@en

type

label

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

@en

prefLabel

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

@en

P1433

Q38801820-125B4078-5D3A-4B30-BDCD-7E953FD58F6F

P1476

Q38801820-E7F5CA33-2C65-47B7-BF26-068A6B6CA805

P2093

Q38801820-53749855-6389-463D-ADA3-D53AFFBE1F6F

Q38801820-6E1E45D4-62CE-49B4-85CF-69A214DA2911

Q38801820-80F4DAB1-09DC-4A1D-8107-44790D1F5761

Q38801820-E06A979F-A000-435D-A690-488F2F2424CF

Q38801820-E97A9B4B-7FF3-472D-BEAC-D1429737FE86

P2860

Q38801820-0114AB2C-B55A-4040-8D62-99748472443C

Q38801820-088893C0-1A66-478E-8577-13DFB2CB09D1

Q38801820-0C573D3A-F982-4C93-87B5-9BFED712171F

Q38801820-25C641E1-3F7B-42E8-82D4-F4935C082B15

Q38801820-26155199-1939-4CEE-A066-8009293D3301

Q38801820-29490BD4-242E-4BB7-B38D-29CEDA875694

Q38801820-2C73883A-8E51-48D4-AF42-6C41F8A5B763

Q38801820-330E7915-C83E-4C12-9082-B4D6F81FE132

Q38801820-4185DC69-B4C7-4B98-8AE1-5ECB9918AC28

Q38801820-4253B5F2-900E-4446-BCC4-205DC2B4E22A

P304

Q38801820-007E7DCA-794A-499D-9E30-912865846818

P31

Q38801820-69CAD9ED-4D39-41DD-ABEC-EC8162B38277

P356

Q38801820-5BBB793A-2FE2-4CEE-BCAF-C2C924379197

P433

Q38801820-B3C4858A-9461-4758-AEE1-37C3F62DEB6F

P478

Q38801820-CD93AC4D-D4DE-4A7F-A592-225AAF9C86E5

P50

Q38801820-B7059E42-8556-4F01-8218-1DACC6F696D0

Q38801820-BD088AA2-2AD1-4D75-B72C-F70CF5C215AF

P577

Q38801820-5BCB6F24-F1EC-419D-8FEF-5D0ED4F86652

P698

Q38801820-972DC3F6-CE0F-4091-B86C-12955029B857

P932

Q38801820-4B2EA1EC-06B4-4384-A4A9-43CCD2FA25C2

P356

P1433

Journal of the American Society of Nephrology

P1476

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors

@en

P2093

Julia Wenger

http://www.w3.org/2001/XMLSchema#string

Kevin E Chan

http://www.w3.org/2001/XMLSchema#string

Ravi I Thadhani

http://www.w3.org/2001/XMLSchema#string

Sagar U Nigwekar

http://www.w3.org/2001/XMLSchema#string

Sophia Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Calciphylaxis: risk factors, diagnosis, and treatment

Calciphylaxis in patients on hemodialysis: a prevalence study

Calciphylaxis: natural history, risk factor analysis, and outcome

Observational studies versus randomized controlled trials: avenues to causal inference in nephrology.

Quantifying a rare disease in administrative data: the example of calciphylaxis

Statin use and calcific uremic arteriolopathy: a matched case-control study.

Calciphylaxis: a still unmet challenge.

Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD.

Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.

The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial

P304

3421-3429

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2015091065

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Franklin Maddux

Jeffrey L Hymes

P577

2016-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27080977

http://www.w3.org/2001/XMLSchema#string

P932

5084892

http://www.w3.org/2001/XMLSchema#string